Edition:
India

People: Altimmune Inc (ALT.OQ)

ALT.OQ on NASDAQ Stock Exchange Global Market

11.20USD
28 Oct 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$11.20
Open
$11.40
Day's High
$11.62
Day's Low
$10.98
Volume
153,895
Avg. Vol
822,188
52-wk High
$35.05
52-wk Low
$1.52

Garg, Vipin 

Dr. Vipin K. Garg Ph.D. serves as President, Chief Executive Officer, Director of the Company. He joined Altimmune in November 2018 with over three decades of experience in the biotechnology and pharmaceutical industries. He has a proven track record of building and managing both private and publicly traded companies. Before joining Altimmune, he served as President and CEO of Neos Therapeutics (NASDAQ: NEOS), where he built a commercial-stage biopharmaceutical company launching three branded therapeutic products including Adzenys XR- ODTTM and Cotempla XR-ODTTM the first ever XR-ODTTM medications for the treatment of ADHD. Prior to Neos, he served as president and CEO of Tranzyme Pharma where he progressed a discovery-stage, emerging biotech company to a NASDAQ-listed clinical-stage, drug development company. Prior to joining Tranzyme, Dr. Garg served as Chief Operating Officer of Apex Bioscience, Inc. (acquired by Curacyte AGof Munich, Germany), and held senior management positions at DNX Bio-Therapeutics, Inc. until its acquisition by Baxter Healthcare Corporation, Sunovion Pharmaceuticals, Inc. (formerly known as Sepracor Inc., now a subsidiary of Sumitomo Dainippon Pharma), and Bio-Response Inc. (acquired by Baxter Healthcare Corporation). Dr. Garg received his Ph.D. in Biochemistry in 1982 from the University of Adelaide, Australia, and his M.S. from IARI Nuclear Research Laboratory, New Delhi, India in 1978.

Basic Compensation

Total Annual Compensation, USD 500,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 66,631
Fiscal Year Total, USD 566,631

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --